TABLE 1.
Susceptibility profiles of isolates from both patients
| Antimicrobial(s) | MIC (μg/ml) for isolatea: |
Interpretation (CLSI breakpoint MIC [μg/ml])b | |
|---|---|---|---|
| IE | VAP | ||
| Vancomycin | 2* | 2* | S (≤2) |
| Daptomycin | 1* | 1* | S (≤1) |
| Ceftaroline | 4* | 6* | R (≤1) |
| Clindamycin | >4 | >4 | R |
| Erythromycin | >4 | >4 | R |
| Gentamicin | >8 | >8 | R |
| Levofloxacin | >4 | >4 | R |
| Oxacillin | >2 | >2 | R |
| Linezolid | 1 | 1 | S |
| Rifampin | ≤1 | ≤1 | S |
| Tetracycline | ≤1 | ≤1 | S |
| TMP-SMXc | ≤0.5/9.5 | ≤0.5/9.5 | S |
a
IE, infective endocarditis; VAP, ventilator-associated pneumonia; *, MIC was determined with the Etest.
b
S, susceptible; R, resistant.
c
TMP-SMX, trimethoprim-sulfamethoxazole.